ArticlePloS one2010
Rising population cost for treating people living with HIV in the UK, 1997-2013.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Trial
- The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE.Croatian medical journal · 2021Article
- Global and regional trends of people living with HIV aged 50 and over: Estimates and projections for 2000-2020.PloS one · 2018Article
- Article
- Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study.AIDS research and therapy · 2017Article
- Economic benefits of safety-engineered sharp devices in Belgium - a budget impact model.BMC health services research · 2013Article
- Cost of noninfectious comorbidities in patients with HIV.ClinicoEconomics and outcomes research : CEOR · 2013Review
- Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain.ClinicoEconomics and outcomes research : CEOR · 2013Article
- Counting the cost of not costing HIV health facilities accurately: pay now, or pay more later.PharmacoEconomics · 2012Review
- Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.PloS one · 2012Article
- Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006.PloS one · 2011Article
- Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.Patient preference and adherence · 2011Article
- The efficiency of the EmERGE platform for medically stable people living with HIV in Portugal.Porto biomedical journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe number of people living with HIV (PLHIV) is increasing in the UK. This study estimated the annual population cost of providing HIV services in the UK, 1997-2006 and projected them 2007-2013.
methodsAnnual cost of HIV treatment for PLHIV by stage of HIV infection and type of ART was calculated (UK pounds, 2006 prices). Population costs were derived by multiplying the number of PLHIV by their annual cost for 1997-2006 and projected 2007-2013.
resultsAverage annual treatment costs across all stages of HIV infection ranged from £17,034 in 1997 to £18,087 in 2006 for PLHIV on mono-therapy and from £27,649 in 1997 to £32,322 in 2006 for those on quadruple-or-more ART. The number of PLHIV using NHS services rose from 16,075 to 52,083 in 2006 and was projected to increase to 78,370 by 2013. Annual population cost rose from £104 million in 1997 to £483 million in 2006, with a projected annual cost between £721 and £758 million by 2013. When including community care costs, costs increased from £164 million in 1997, to £683 million in 2006 and between £1,019 and £1,065 million in 2013.
conclusionsIncreased number of PLHIV using NHS services resulted in rising UK population costs. Population costs are expected to continue to increase, partly due to PLHIV's longer survival on ART and the relative lack of success of HIV preventing programs. Where possible, the cost of HIV treatment and care needs to be reduced without reducing the quality of services, and prevention programs need to become more effective. While high income countries are struggling to meet these increasing costs, middle- and lower-income countries with larger epidemics are likely to find it even more difficult to meet these increasing demands, given that they have fewer resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.